TY - JOUR
AU - Cetron, Marty
AB - 1 O CTOBER Clive M. Brown and Martin S. Cetron, Section Editors An editorial feature on globally mobile involves itineraries or activities that in- http://www.cdc.gov/ncidod/dvbid/jence- populations and infectious disease out- crease the risk of JE virus exposure (eg, phalitis/children.htm. breaks, written by the Centers for Disease extensive outdoor or nighttime activities). Editor’s comment. Japanese encepha- Control and Prevention’s Division of The only JE vaccine currently available litis is a rare disease for travelers but is Global Migration and Quarantine in the United States is an inactivated potentially fatal, with a high case-fatality Vero cell culture-derived vaccine (JE-VC), rate. Clinicians should consider a number manufactured as Ixiaro, which is licensed of factors when deciding on the use of JE JapaneseEncephalitisVaccine for use in persons 17 years of age and vaccine for travelers, including the low and International Travel, 2011 older. Ixiaro is also available in the Eu- risk of travel-associated JEV disease, the Japanese encephalitis (JE) virus, a ropean Union, Australia, Canada, and high morbidity and mortality when JE mosquito-borne flavivirus, is the most Switzerland. JE-VC is given in a primary occurs, the low probability of serious series of two doses administered in- adverse events after immunization, the common vaccine-preventable 
TI - Crossing Borders: One World, Global Health
JF - Clinical Infectious Diseases
DO - 10.1093/cid/cir646
DA - 2011-10-01
UR - https://www.deepdyve.com/lp/oxford-university-press/crossing-borders-one-world-global-health-0APEY0rZ0l
SP - iii
EP - v
VL - 53
IS - 7
DP - DeepDyve
ER -